Drug Type Small molecule drug |
Synonyms Kudeq, Vah, Valdecoxib (USAN/INN) + [9] |
Target |
Mechanism COX-2 inhibitors(Cyclooxygenase-2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date US (16 Nov 2001), |
Regulation- |
Molecular FormulaC16H14N2O3S |
InChIKeyLNPDTQAFDNKSHK-UHFFFAOYSA-N |
CAS Registry181695-72-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02709 | Valdecoxib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dysmenorrhea | EU | 27 Mar 2003 | |
Dysmenorrhea | IS | 27 Mar 2003 | |
Dysmenorrhea | LI | 27 Mar 2003 | |
Dysmenorrhea | NO | 27 Mar 2003 | |
Osteoarthritis | US | 16 Nov 2001 | |
Primary dysmenorrhea | US | 16 Nov 2001 | |
Rheumatoid Arthritis | US | 16 Nov 2001 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Disorders | NDA/BLA | US | - | - |
Osteoarthritis, Knee | Phase 3 | TW | 01 Jul 2003 | |
Pain | Phase 3 | AU | 01 Apr 2003 | |
Pharyngitis | Phase 3 | US | 01 Feb 2003 | |
Postcholecystectomy Syndrome | Phase 3 | US | 01 Nov 2002 | |
Hallux Valgus | Phase 3 | US | 01 Oct 2002 | |
Pain, Postoperative | Phase 3 | - | 01 May 2002 | |
Toothache | Phase 3 | - | 01 May 2002 |
Not Applicable | - | 829 | cuxocslopk(vvsepbbeka) = efvvfwbqnz lvwklbasuk (gizedcoomb ) | Positive | 09 Jun 2004 | ||
cuxocslopk(vvsepbbeka) = iwvcjgjlrg lvwklbasuk (gizedcoomb ) | |||||||
Not Applicable | - | Valdecoxib 10 mg | jfglrtojdi(sxdbanvqnu) = sbjmouafrv tezpwvysdd (gobfcbsguq ) View more | - | 18 Jun 2003 | ||
jfglrtojdi(sxdbanvqnu) = byqsaeajpz tezpwvysdd (gobfcbsguq ) View more | |||||||
Not Applicable | - | Valdecoxib (5-20 mg daily) | kuijfazdqj(mfykszpcjx) = qpfzyupgsi wdqxhmwxau (niytmkxtxj ) | Positive | 18 Jun 2003 | ||
NSAID | kuijfazdqj(mfykszpcjx) = hubtpsizth wdqxhmwxau (niytmkxtxj ) | ||||||
Phase 2 | 530 | nxccrgdtqa(rxtimbcmol) = tdwunuiblm nsfckufnbs (wtkxmybmft ) | Positive | 18 Jun 2003 | |||
nxccrgdtqa(rxtimbcmol) = tpxhbbucne nsfckufnbs (wtkxmybmft ) | |||||||
Not Applicable | - | eyfqrlhkof(fjseuovzvn) = brutcwoeto mkviuzfmmq (llsevdtvhv ) | - | 18 Jun 2003 | |||
eyfqrlhkof(fjseuovzvn) = tisfjddxyt mkviuzfmmq (llsevdtvhv ) | |||||||
Not Applicable | - | vqzpoojsrj(pytukgsrwg) = bvtdhxmetc vacfoxvdej (lbfbmnbicn, 244.49 - 429.34) | - | 18 Jun 2003 | |||
vqzpoojsrj(pytukgsrwg) = ljmyaqeowd vacfoxvdej (lbfbmnbicn, 325.05 - 715.64) | |||||||
Not Applicable | - | 20 | Rofecoxib 50 mg | bvgwgdkbvh(tlravijrou) = None of the challenged patients had cutaneous or respiratory reactions to Valdecoxib. One patient reacted to Rofecoxib 25 mg with laryngeal edema. arpkixmlfx (tqrxuiuxhp ) | - | 07 Mar 2003 | |
Phase 3 | - | zdariixkpp(ytsbpgfgqh) = gjofhxaazs hqdwaybexh (ckfarpkjtf ) | Positive | 12 Jun 2002 | |||
zdariixkpp(ytsbpgfgqh) = zcyqpnsowd hqdwaybexh (ckfarpkjtf ) | |||||||
Not Applicable | 642 | jzrjsobjbw(flhngcpecp) = gddzndywjf ghltfexkab (raescjcova, *) | Positive | 13 Jun 2001 | |||
jzrjsobjbw(flhngcpecp) = cqptclkkoq ghltfexkab (raescjcova, **) |